Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ686MR)

This product GTTS-WQ686MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ686MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1539MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ8195MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ11772MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ332MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ14001MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ11877MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ5430MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ5909MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW